Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936363 · ClinicalTrials.gov registry record · Phase 2
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT01936363 is a Phase 2 study of Ovarian Cancer that has completed, run by EMD Serono. The registered enrollment target is 65 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01936363, a Phase 2 study of Ovarian Cancer, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib placebo administered once per day compared to pimasertib administered twice per day plus SAR245409 placebo administered once per day in participants with previously treated unresectable low-grade serous ovarian or peritoneal carcinoma or serous borderline ovarian or peritoneal tumors.
Conditions Studied
Interventions
- DRUG SAR245409
- DRUG Pimasertib once daily
- DRUG Pimasertib placebo
- DRUG SAR245409 placebo
- DRUG Pimasertib twice daily
Study Locations (20)
Ohio
- Research site - Cincinnati
- Research site - Columbus
- Research site - Middletown
Massachusetts
- Research site - Boston
- Research site - Boston
Michigan
- Research site - Ann Arbor
- Research site - Detroit
Missouri
- Research site - Kansas City
- Research site - St Louis
Georgia
- Research site - Augusta
Illinois
- Research site - Chicago
Indiana
- Research site - Indianapolis
Maryland
- Research site - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2013-09-30 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936363
The ClinicalTrials.gov registry entry for NCT01936363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which SAR245409 is the first listed.
NCT01936363 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ohio, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT01936363 about?
NCT01936363 is a clinical study titled "Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer". This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib placebo administered once per day compared to pimasertib administered twice per day plus SAR245409 placebo administere...
What is the current status of trial NCT01936363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2013-09-30. Estimated completion is 2017-11-30.
What conditions does trial NCT01936363 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT01936363?
The interventions under investigation include: SAR245409 (DRUG), Pimasertib once daily (DRUG), Pimasertib placebo (DRUG), SAR245409 placebo (DRUG), Pimasertib twice daily (DRUG).
Who is sponsoring clinical trial NCT01936363?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01936363 being conducted?
This trial has 20 study locations across Georgia, Illinois, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.